摘要
目的对比研究瑞舒伐他汀和辛伐他汀治疗老年冠心病伴高胆固醇血症的疗效。方法选取2009年3月～2012年6月入院进行治疗的冠心病伴高胆固醇血症患者118例,随机分为对照组和研究组,对照组患者采用辛伐他汀进行治疗,研究组患者采用瑞舒伐他汀进行治疗,治疗前后观察记录两组患者血脂变化,记录患者不良反应及并发症发生情况。结果治疗后,研究组患者TC及LDL-C水平较对照组下降明显,差异具有统计学意义(P<0.05),但是在TG及HDL-C水平两项上差异无统计学意义(P>0.05)。两组均未出现影响病情的严重不良反应,肝肾功能正常,不良反应主要以恶心呕吐、食欲下降以及轻微的上呼吸道感染为主。结论小剂量瑞舒伐他汀较辛伐他汀在降低TC、LDL-C水平方面疗效显著,安全性高,研究前景广阔。
Objective To compare the effects of rosuvastatin and simvastatin in the treatment of elderly patients with coronary heart disease associated with hypercholesterolemia. Methods One hundred and eighteen patients with hyper- cholesterolemia who were treated in our hospital from March 2009 to June 2012 were randomly divided into control group and study group. The control group were treated with simvastatin, the study group were treated with rosuvastatin. The hyperlipidemia changes before and after treatment of two groups were observed, adverse reactions and complica- tions were recorded. Results After treatment, compared with the control group, the study group of patients with TC and LDL-C target levels decreased significantly, and the difference was statistically significant （P 〈 0.05）, but there was no difference in TG and HDL-C levels between two groups （P 〉 0.05）. Two groups were not serious adverse reactions af- fect their condition, normal liver and kidney function, and adverse reactions to nausea and vomiting, loss of appetite and mild upper respiratory tract infection. Conclusion Low-dose rosuvastatin compared with simvastatin has signifi- cant efficacy in reducing the level of TC, LDL-C, and has higher security.
出处
《中国当代医药》
2013年第9期70-71,共2页
China Modern Medicine
